Alvotech Reports Financial Results for the First Nine Months of 2024
13 nov. 2024 16h05 HE
|
Alvotech
Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine...
Alvotech birtir fjárhagsuppgjör fyrir fyrstu níu mánuði ársins 2024
13 nov. 2024 16h05 HE
|
Alvotech
Heildartekjur á fyrstu níu mánuðum ársins jukust um 300 milljónir dala frá sama tímabili árið 2023, í 339 milljónir dala, þar af voru tekjur 103 milljónir dala á þriðja ársfjórðungi Tekjur af vörusölu...
Alvotech Reports Financial Results for the First Nine Months of 2024
13 nov. 2024 16h05 HE
|
Alvotech
Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine...
Alvotech fundar með fjárfestum á heilbrigðisráðstefnum Citi og Evercore fjárfestingabankanna dagana 4. og 5. desember 2024
07 nov. 2024 08h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) tekur þátt árlegum í heilbrigðisráðstefnum alþjóðlegu fjárfestingabankanna Citi og Evercore, dagana 4.-5. desember n.k. Auk þess að funda með fjárfestum munu stjórnendur...
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
07 nov. 2024 08h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Citi’s 2024...
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
07 nov. 2024 08h00 HE
|
Alvotech
REYKJAVIK, Iceland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir AVT05, fyrirhugaða líftæknilyfjahliðstæðu við Simponi (golimumab)
04 nov. 2024 07h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) og samstarfsaðili þess, alþjóðlega lyfjafyrirtækið Advanz Pharma tilkynntu í dag að Lyfjastofnun Evrópu (EMA) hafi samþykkt að taka til umsagnar umsókn um markaðsleyfi fyrir...
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
04 nov. 2024 07h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global...
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
04 nov. 2024 07h00 HE
|
Alvotech
REYKJAVIK, Iceland and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
30 oct. 2024 08h30 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first nine months of...